KLF transcription factor 1
Ultimo aggiornamento 4 Mar 2025
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Versione audio
- Aggiungi alle fonti preferite su Google
The KLF1 gene provides instructions for making a protein that acts as a transcription factor, which means it attaches (binds) to specific regions of DNA and helps control the activity of particular genes. Specifically, the KLF1 protein helps control the activity of genes that are involved in the differentiation of red blood cells by regulating the final stages of red blood cell development (erythropoiesis).
Normal function
The KLF1 gene provides instructions for making a protein that acts as a transcription factor, which means it attaches (binds) to specific regions of DNA and helps control the activity of particular genes. Specifically, the KLF1 protein helps control the activity of genes that are involved in the differentiation of red blood cells by regulating the final stages of red blood cell development (erythropoiesis).
The KLF1 protein plays an important role in the production of hemoglobin, which is the protein in red blood cells that carries oxygen to cells and tissues throughout the body. During development, the KLF1 protein regulates the switch from the production of fetal hemoglobin, which is prevalent during embryonic development and early infancy, to the adult form of hemoglobin, which is produced throughout life.
Conditions referring to this gene or chromosome
Altri nomi
EKLF
Erythroid krueppel-like transcription factor
Related patient information and medicines
Patient information leaflet
Leucemia linfoblastica acuta
This is done in a similar way to a lumbar puncture (described above) and is called an intrathecal injection. In some cases, radiotherapy to the brain is also used. Stem cell transplantation (SCT) SCT - sometimes called bone marrow transplantation - may be performed. It may be used for cases where the leukaemia has come back (recurred) following.
Patient information leaflet
Emofilia
Emofilia is a rare bleeding disorder that affects your ability to make a clot. The blood contains substances called clotting factors that work with platelets to form a clot. When you injure yourself the clot stops you bleeding. Haemophilia is a condition where there is a deficiency of clotting factors, so people with this condition usually have.
Patient information leaflet
Trattamento del diabete di tipo 2
If any of the above risk factors apply to you: If you are not currently on glucose-lowering treatment, your doctor will usually recommend you start taking metformina first. As soon as you are settled on metfor... GLP-1 (glucagon-like peptide-1) mimetics - exenatide, dulaglutide, liraglutide, lixisenatide and semaglutide Exenatide , dulaglutide,.
Patient information leaflet
Test di coagulazione del sangue
Test di coagulazione del sangue are used to diagnose and assess bleeding problems and to monitor people who take warfarin or other anticoagulant medicines. You may be advised to have blood clotting tests: If you have a suspected bleeding disorder. These chemicals then react with other chemicals and proteins in th... There are 13 known clotting factors which.
Patient information leaflet
Posso prendere Apixaban e Rybelsus insieme?
These two medicines work in different ways and do not typically interfere with how the other is absorbed, broken down, or removed from the body. Why this happens Apixaban is an anticoagulant (blood thinner) that works by blocking a clotting factor called Factor Xa. Rybelsus è a GLP-1 receptor agonist used for type 2 diabetes that mimics a natural.
Patient information leaflet
Insulina
Insulina è a hormone made naturally in the body by the pancreas. This hormone controls the level of sugar (glucose) in the blood. People who have type 1 diabetes need to have regular insulin injections. In type 1 diabetes, the body stops making insulin and the blood sugar level goes very high. Some people who have type 2 diabetes may also need to.
Ulteriori letture e riferimenti
- KLF transcription factor 1; MedlinePlus, National Library of Medicine.
- Bieker JJ, Philipsen S. Erythroid Kruppel-Like Factor (KLF1): A Surprisingly Versatile Regulator of Erythroid Differentiation. Adv Exp Med Biol. 2024;1459:217-242. doi: 10.1007/978-3-031-62731-6_10.
- Iolascon A, Andolfo I, Russo R. Congenital dyserythropoietic anemias. Blood. 2020 Sep 10;136(11):1274-1283. doi: 10.1182/blood.2019000948.
- Russo R, Iolascon A, Andolfo I, Marra R, Rosato BE. Updates on clinical and laboratory aspects of hereditary dyserythropoietic anemias. Int J Lab Hematol. 2024 Aug;46(4):595-605. doi: 10.1111/ijlh.14307. Epub 2024 May 15.
Partecipa alla conversazione
Condividi i tuoi pensieri o esperienze con gli altri nel nostro comunità di pazienti.
Chiedi, condividi, connettiti.
Esplora le discussioni, fai domande e condividi esperienze su centinaia di argomenti di salute.
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
Abbonandoti accetti i nostri Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.